Somewhere in the neck, tucked against the fork where the carotid artery splits in two, sits a structure so small it weighs less than a paper clip. Most people have never heard of it. Cardiologists rarely talk about it. Yet researchers now believe it may be silently driving blood pressure up in millions of people who can’t get their numbers down no matter what they take.
The carotid body weighs between 18 and 20 milligrams in most adults, with a size ranging from roughly 2 to 3 millimeters. For comparison, a single grain of rice is about the same length. This organ is so unremarkable in its proportions that it spent most of medical history in the background, acknowledged mainly in anatomy textbooks. Its job, as far as anyone knew, was to monitor oxygen and carbon dioxide in the blood and nudge the brain to adjust breathing. Useful, sure, but not exactly a headline grabber.
What changed the picture was a series of experiments involving animals with high blood pressure. Researchers led by Professor Julian Paton found that by removing the carotid body’s connection to the brain in rodents with high blood pressure, blood pressure fell and remained low. The finding was surprising enough that it prompted a decade of follow-up work. Then came a human trial, and the results were harder to explain away.
What the Carotid Body Actually Does
Carotid bodies normally “sniff” the levels of oxygen in the blood and, like a thermostat, respond when levels get too low, signaling the brain to increase breathing rate and blood pressure. That response is supposed to be temporary, a short correction to a short problem. Low oxygen goes up, blood pressure returns to baseline, everything resets.
Normally, the carotid body acts to regulate the amount of oxygen and carbon dioxide in the blood. It’s stimulated when oxygen levels fall, as occurs when you hold your breath, triggering a dramatic increase in breathing and blood pressure until blood oxygen levels are restored. The carotid body sits at the bifurcation (the fork) of the common carotid artery on each side of the neck, where it has constant access to arterial blood. In healthy individuals, the carotid bodies have very low levels of activity, but researchers discovered these tiny organs become hyperactive in conditions of hypertension, generating what Professor Paton described as “aberrant or tonic discharge” sent into the brain regions controlling cardiovascular activity.
The mechanism involves the carotid body sending excess signals to the sympathetic nervous system, the body’s “fight or flight” network. The carotid body is involved with both the development and maintenance of neurogenic hypertension, associated with pathological development of both hyperreflexia and hypertonicity, so-called carotid body hyperexcitability. Once that feedback loop gets stuck in the “on” position, blood pressure doesn’t simply tick up during a moment of stress and then settle back down. It stays elevated.
Carotid body hyperactivity and hypertrophy have been observed in chronic conditions including hypertension, heart failure, diabetes, and sleep apnea. This pattern across multiple diseases suggests the carotid body isn’t just a bystander reacting to illness. It may be an active contributor to cardiovascular dysfunction that has been overlooked for decades.
A Clinical Trial That Raised Eyebrows
The research study “Unilateral Carotid Body Resection in Resistant Hypertension: A Safety and Feasibility Trial” was led by Professor Julian Paton at the University of Bristol and Dr. Angus Nightingale, a cardiology consultant at the Bristol Heart Institute, and was published in the Journal of the American College of Cardiology: Basic to Translational Science.
The patients enrolled weren’t people with mildly elevated readings they hadn’t gotten around to treating. Resistant hypertension is defined as blood pressure above goal despite the use of maximum or optimal doses of three or more antihypertensive medications, including a diuretic. These are patients who have tried the pharmacological toolkit and found it insufficient.
The research indicates that the carotid bodies appear to be a cause of high blood pressure, and the clinical team showed that removing one carotid body from some patients with high blood pressure caused an immediate and sustained fall in blood pressure. The trial was a first-in-man, proof-of-principle study testing safety and feasibility. The procedure was unilateral, meaning only one of the two carotid bodies was removed, which matters clinically because the remaining organ continues to monitor blood oxygen normally.
Dr. Nightingale said: “The falls in blood pressure we have seen are impressive – more than you would see with pharmacological medication.”
Specifically, a 2016 JACC trial found that unilateral carotid body resection lowered blood pressure by 26 mm Hg in 57% of patients with drug-resistant hypertension across 15 participants. A 26 mm Hg reduction is not a rounding error. For context, most blood pressure medications lower systolic readings by 5 to 10 mm Hg at standard doses. Finding that kind of effect from a single surgical procedure on an organ the size of a peppercorn was, to put it plainly, unexpected.
The people who were successfully treated had naturally raised carotid body activity at rest – they breathed more and had exaggerated breathing responses to reduced oxygen levels in the blood. That detail is important. Not every person with high blood pressure is a candidate. The procedure appears to work specifically in those whose hypertension is being driven, at least in part, by a chronically overactive carotid body.
The Drug Target Hidden Inside This Tiny Organ
Surgery is one route. But researchers have also identified a specific molecular target inside the carotid body that could, in theory, be switched off with a drug rather than a scalpel.
Scientists found they could “turn down the alarm signals emanating from the carotid body in conditions of hypertension,” and the new drug target identified within the carotid body is a receptor for the ATP molecule called the P2X3 receptor. ATP (adenosine triphosphate) is the body’s primary energy molecule, but it also acts as a signaling compound in nerve tissue. In hyperactive carotid bodies, too much ATP appears to be flooding the P2X3 receptor, triggering excess sympathetic nervous system activity.
The research, led by Professor Paton and published in Nature Medicine, found that blocking the P2X3 receptor reduced this signaling. Researchers demonstrated that the upregulation and functional importance of purinergic P2X3 receptors drives carotid body hyperexcitability in hypertension, and that carotid body denervation or resection has been shown to be an effective treatment in animal models and in a subset of human patients.
Resection of the carotid body or blockade of P2X3 receptors in the carotid body significantly reduced blood pressure and muscle sympathetic nerve activity in patients with hypertension. That finding, replicated across both animal models and early human data, is what makes the P2X3 pathway attractive as a drug target: it could potentially be addressed pharmacologically, without surgery, in a highly targeted way.
Instead of treating high blood pressure by targeting the functions within end organs such as the heart, kidneys, and vasculature, this approach aims to reduce nervous system activity from a sensory organ – the carotid body – that when activated can cause blood pressure to rise uncontrollably. That’s a fundamentally different philosophy from the drugs currently on pharmacy shelves.
Why This Matters for the Millions Who Can’t Get Their Numbers Down
According to a 2025 JACC analysis, applying updated 2017 ACC/AHA diagnostic criteria to data from 2021 to 2023 yields a hypertension prevalence of 47.6% among U.S. adults. That’s close to half the adult population. In 2022, nearly 690,000 deaths in the U.S. were caused by complications of hypertension.
Despite the scale of the problem, treatment control rates remain poor. According to data from the ACC, nearly four out of five U.S. adults with hypertension have blood pressure above the 2025 AHA/ACC guideline goal. The CDC’s most recent National Health Statistics data shows only 20.7% of U.S. adults with hypertension have their blood pressure controlled to below 130/80 mm Hg. That’s a treatment gap no combination of diet advice and standard medications has closed.
Within that broader group, roughly 8% to 14% of the one billion patients with hypertension worldwide are drug-resistant or intolerant to medications. That’s potentially 80 to 140 million people for whom the current treatment playbook has run out of moves. The carotid body resection trial was specifically designed for them.
For people managing borderline-to-moderate hypertension with standard medications, natural lifestyle approaches such as dietary sodium reduction, regular aerobic exercise, and stress management remain the first line of non-pharmacological intervention. But the carotid body research opens a different lane entirely: a biological root-cause intervention for cases where those measures have already been exhausted.
Research published in 2025 in the journal Function confirmed that patients with obstructive sleep apnea exhibit overactive sympathetic nervous systems and hypertension, mediated through hyperactive carotid body chemoreflex. Sleep apnea is already one of the most common comorbidities in resistant hypertension, and this finding suggests the two conditions may share a single upstream driver in the carotid body, not just run in parallel.
Read More: Major Study Links 99% of Heart Attacks and Strokes With 4 Risk Factors
What to Do Now
Carotid body resection is not an elective procedure you’ll find on a surgical menu at your local hospital. The 2016 trial was a safety-and-feasibility study, and more research is needed before any wide clinical rollout. The P2X3 drug pathway is earlier still, with human trials ongoing. For most people, this science is a few years from a consultation room near them.
What the research does offer is a reframe worth carrying into your next appointment. If you or someone you know has genuinely resistant hypertension – defined specifically as blood pressure that stays above goal despite maximum doses of three or more medications including a diuretic – the question worth raising with a cardiologist is whether the sympathetic nervous system is the real driver, and whether any interventional options exist for that pathway.
The carotid body blood pressure connection also reframes the relationship between sleep apnea and heart risk. If the carotid body is a shared mechanism between the two conditions, then treating sleep apnea aggressively may do more for blood pressure than adding a fourth medication. Getting a sleep study if you have both conditions is a concrete, immediately actionable step. The organ doing this is barely the size of a grain of rice. The implications, it turns out, are considerably larger.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.